PROCISE cLC Sequencing System 2 Cart w/PC

PROCISE cLC 测序系统 2 推车（带 PC）

• 批准号: 6730937
• 负责人: DAVID B. TEPLOW
• 金额: $ 18.44万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-04-01 至 2005-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6730937
• 关键词: biomedical automation; biomedical equipment purchase; computer assisted sequence analysis; protein sequence

DESCRIPTION (provided by applicant): Support is requested for the purchase of an Applied Biosystems PROCISE (r) cLC Sequencing System. Applied Biosystems is the only manufacturer of protein sequenators. The PROCISE is a state-of-the-art instrument for automated Edman protein sequencing. The instrument will replace an obsolete Model 477A sequenator that originally was purchased 15 years ago. The PROCISE is approximately 100-fold more sensitive than the 477A, which is currently the sole protein sequenator in a core protein chemistry facility, the Biopolymer Laboratory (BPL), at Brigham and Women's Hospital (BWH). Since 1984, the BPL has provided standard sequencing services to users at BWH, Harvard Medical School and its affiliated teaching hospitals, and other institutions in the US and in foreign countries. In addition, the BPL is a world center for radiosequence analysis, which is done by relatively few laboratories. This technique uses pre.facto radiolabeled protein samples to identify positions of specific amino acids through the periodicity of radioactivity detected in each cycle of the Edman chemistry. This highly sensitive (attomolar) method allows sequence determination of samples not otherwise amenable to sequence analysis or to mass spectrometric characterization. Twelve NIH-funded projects comprise our "major user group." The number of projected sequencing samples, which will keep the new instrument running continuously, and the need for radiosequencing capabilities, make purchase of the PROCISE instrument necessary to achieve the aims of the NIH grants funding the user group. These aims address key questions related to important human diseases, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and osteoporosis. In addition to providing the means to study these diseases, the improved sensitivity of the PROCISE will open up new opportunities for researchers studying low abundance proteins and who were precluded from applying sequencing methods to their projects due to the relatively low sensitivity of the obsolete 477 instrument. Importantly, as has happened countless times following the introduction of new or improved instrumentation, we fully expect that unforeseen advances in the understanding and treatment of human disease will be enabled by the availability of the PROCISE instrument.

描述（由申请人提供）：请求支持购买 Applied Biosystems PROCISE (r) cLC 测序系统。 Applied Biosystems 是唯一一家蛋白质测序仪制造商。 PROCISE 是最先进的自动 Edman 蛋白质测序仪器。该仪器将取代 15 年前购买的过时的 477A 型测序仪。 PROCISE 的灵敏度比 477A 大约高 100 倍，477A 是目前布莱根妇女医院 (BWH) 核心蛋白质化学设施生物聚合物实验室 (BPL) 中唯一的蛋白质测序仪。自1984年以来，BPL一直为BWH、哈佛医学院及其附属教学医院以及美国和国外其他机构的用户提供标准测序服务。此外，BPL 是世界无线电序列分析中心，由相对较少的实验室完成。该技术使用预先放射性标记的蛋白质样品，通过埃德曼化学每个循环中检测到的放射性周期性来识别特定氨基酸的位置。这种高度灵敏（阿摩尔）方法可以对原本不适合进行序列分析或质谱表征的样品进行序列测定。十二个 NIH 资助的项目构成了我们的“主要用户组”。预计测序样本的数量将使新仪器持续运行，并且需要无线电测序功能，因此有必要购买 PROCISE 仪器，以实现 NIH 拨款资助用户组的目标。这些目标解决与重要人类疾病相关的关键问题，包括阿尔茨海默病、帕金森病、多发性硬化症和骨质疏松症。除了提供研究这些疾病的手段之外，PROCISE 灵敏度的提高将为研究低丰度蛋白质的研究人员以及由于过时的 477 仪器的灵敏度相对较低而无法将测序方法应用于其项目的研究人员提供新的机会。 重要的是，正如在引入新的或改进的仪器之后无数次发生的那样，我们完全期望 PROCISE 仪器的可用性将在人类疾病的理解和治疗方面取得不可预见的进步。